Brokerages Expect Syros Pharmaceuticals Inc (SYRS) to Announce -$0.57 EPS

Wall Street brokerages expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to post earnings per share (EPS) of ($0.57) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Syros Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.56). Syros Pharmaceuticals reported earnings per share of ($0.47) in the same quarter last year, which would suggest a negative year-over-year growth rate of 21.3%. The firm is expected to issue its next earnings report on Monday, March 19th.

On average, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($2.12) per share for the current financial year, with EPS estimates ranging from ($2.14) to ($2.10). For the next year, analysts forecast that the company will post earnings of ($2.60) per share, with EPS estimates ranging from ($3.69) to ($2.00). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Syros Pharmaceuticals.

A number of analysts have weighed in on the stock. Piper Jaffray Companies reissued an “overweight” rating and set a $30.00 target price on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. HC Wainwright reissued a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, December 21st. Oppenheimer restated a “buy” rating and set a $28.00 price target on shares of Syros Pharmaceuticals in a research report on Thursday, December 7th. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Friday, January 5th. Finally, Roth Capital initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday, October 23rd. They set a “neutral” rating and a $15.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $22.36.

In related news, Director Srinivas Akkaraju bought 209,424 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was purchased at an average price of $9.55 per share, for a total transaction of $1,999,999.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jeremy P. Springhorn bought 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average price of $9.08 per share, with a total value of $136,200.00. The disclosure for this purchase can be found here. Insiders have bought 334,198 shares of company stock valued at $3,127,458 in the last 90 days. Insiders own 33.60% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Adalta Capital Management LLC bought a new position in Syros Pharmaceuticals in the 4th quarter valued at about $111,000. Two Sigma Investments LP boosted its position in shares of Syros Pharmaceuticals by 80.3% during the 4th quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock valued at $206,000 after purchasing an additional 9,439 shares in the last quarter. Two Sigma Advisers LP bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at about $105,000. ARK Investment Management LLC boosted its position in shares of Syros Pharmaceuticals by 519.7% during the 4th quarter. ARK Investment Management LLC now owns 834,757 shares of the company’s stock valued at $8,122,000 after purchasing an additional 700,058 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at about $191,000. Hedge funds and other institutional investors own 48.41% of the company’s stock.

Shares of Syros Pharmaceuticals (SYRS) opened at $10.09 on Thursday. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $24.38.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thelincolnianonline.com/2018/02/18/brokerages-expect-syros-pharmaceuticals-inc-syrs-to-announce-0-57-eps.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply